LATEST NEWSThu, 27. October 2022Starting signal to set up a therapy hub at Science City Hamburg Bahrenfeld
LATEST NEWSWed, 29. April 2020Ascenion GmbH and Innovationsstarter Fonds Hamburg GmbH acquire shares in PROVIREX
LATEST NEWSSun, 1. March 2020PROVIREX Genome Editing Therapies GmbH and Pantherna Therapeutics GmbH are developing lipid-based delivery systems for mRNA-directed genome editing of lymphocytes for the treatment of HIV and other life-threatening persistent viral diseases.
LATEST NEWSFri, 29. November 2019PROVIREX’s proprietary Brec1 technology enters clinical testing as a first-in-human phase
